The promise of DNA damage response inhibitors for the treatment of glioblastoma

Glioblastoma (GBM), the most aggressive primary brain tumor, has a dismal prognosis. Despite our growing knowledge of genomic and epigenomic alterations in GBM, standard therapies and outcomes have not changed significantly in the past two decades. There is therefore an urgent unmet need to develop...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neurooncol Adv
Main Authors: Majd, Nazanin K, Yap, Timothy A, Koul, Dimpy, Balasubramaniyan, Veerakumar, Li, Xiaolong, Khan, Sabbir, Gandy, Katilin S, Yung, W K Alfred, de Groot, John F
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2021
Assuntos:
Reviews
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7954093/
https://ncbi.nlm.nih.gov/pubmed/33738447
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdab015
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados